|
|
|
Insider
Information: |
Svennilson Peter |
Relationship: |
Director, 10% Owner |
City: |
Seattle |
State: |
WA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
8 |
|
Direct
Shares |
21,988,435 |
|
Indirect Shares
|
28,546,447 |
|
|
Direct
Value |
$116,353,630 |
|
|
Indirect Value
|
$295,076,712 |
|
|
Total
Shares |
50,534,882 |
|
|
Total
Value |
$411,430,342 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
32
|
4
|
Stock
price went up :
|
32
|
1
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
32.0
|
32.0
|
Percentage
Gain/Loss : |
66.6%
|
-51.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immune Design Corp. |
IMDZ |
Managing Partner, 10% ... |
2019-04-02 |
0 |
2017-10-27 |
6,642,942 |
Premium* |
|
Constellation Pharmaceuticals Inc |
CNST |
10% Owner |
2021-02-17 |
2,584,957 |
2021-02-17 |
3,645,681 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
Director, 10% Owner |
2018-10-02 |
0 |
2018-10-02 |
3,102,934 |
Premium* |
|
Ngm Biopharmaceuticals Inc |
NGM |
Managing Partner, 10% ... |
2020-08-28 |
17,988,843 |
2020-08-28 |
190,000 |
Premium* |
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director, 10% Owner |
|
0 |
2020-04-28 |
4,768,181 |
Premium* |
|
Revolution Medicines, Inc. |
RVMD |
Director |
2021-04-28 |
20,302 |
2021-04-28 |
3,145,258 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2021-05-05 |
1,394,333 |
2021-05-05 |
1,420,954 |
Premium* |
|
Rapt Therapeutics, Inc. |
RAPT |
Director, 10% Owner |
2020-08-17 |
0 |
2020-09-22 |
5,630,497 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
|
2021-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
809,826 |
48,406 |
0 |
- |
|
NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
|
2021-05-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,488,027) |
0 |
0 |
- |
|
NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
|
2021-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,000,000) |
1,394,333 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-28 |
4 |
AS |
$42.50 |
$4,250 |
I/I |
(100) |
1,775,236 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-27 |
4 |
AS |
$42.65 |
$994,922 |
I/I |
(23,326) |
1,775,289 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-26 |
4 |
AS |
$42.85 |
$2,270,174 |
I/I |
(52,984) |
1,787,660 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-09 |
4 |
AS |
$43.83 |
$1,082,541 |
I/I |
(24,701) |
1,815,761 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-08 |
4 |
AS |
$44.80 |
$2,071,204 |
I/I |
(46,228) |
1,828,862 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-07 |
4 |
AS |
$45.60 |
$1,274,783 |
I/I |
(27,953) |
1,853,380 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-06 |
4 |
AS |
$48.06 |
$1,898,441 |
I/I |
(39,500) |
1,868,205 |
0 |
% |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2021-04-05 |
4 |
AS |
$46.65 |
$849,817 |
I/I |
(18,215) |
1,889,154 |
0 |
% |
|
CNST |
Constellation Pharmaceuti... |
10% Owner |
|
2021-02-17 |
4 |
S |
$36.95 |
$369,503 |
I/I |
(10,000) |
99,155 |
0 |
% |
|
CNST |
Constellation Pharmaceuti... |
10% Owner |
|
2020-12-14 |
4 |
OE |
$1.55 |
$46,666 |
D/D |
30,107 |
2,584,957 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2020-12-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,046,868) |
0 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2020-12-09 |
4 |
A |
$0.00 |
$0 |
I/I |
46,914 |
46 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
13,068 |
20,302 |
0 |
- |
|
RVMD |
Revolution Medicines, Inc... |
Director |
|
2020-11-16 |
4 |
S |
$36.40 |
$73,788,478 |
I/I |
(2,027,156) |
2,429,180 |
0 |
% |
|
RAPT |
Rapt Therapeutics, Inc. |
Director |
|
2020-09-22 |
4 |
S |
$30.85 |
$18,756,800 |
I/I |
(608,000) |
3,835,679 |
0 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-08-28 |
4 |
B |
$17.89 |
$467,555 |
D/D |
26,135 |
1,762,936 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
Managing Partner |
|
2020-08-27 |
4 |
B |
$17.79 |
$646,827 |
D/D |
36,359 |
1,736,801 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-08-25 |
4 |
B |
$18.00 |
$1,800 |
D/D |
100 |
1,700,442 |
2.37 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-08-24 |
4 |
B |
$17.96 |
$197,991 |
D/D |
11,024 |
1,700,342 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-08-21 |
4 |
B |
$17.97 |
$131,558 |
D/D |
7,321 |
1,689,318 |
2.45 |
% |
|
NGM |
Ngm Biopharmaceuticals In... |
General Partner |
|
2020-08-17 |
4 |
B |
$17.89 |
$114,943 |
D/D |
6,425 |
1,681,997 |
2.45 |
% |
|
RAPT |
Rapt Therapeutics, Inc. |
Director |
|
2020-08-17 |
4 |
S |
$22.75 |
$12,254,379 |
I/I |
(538,654) |
4,443,679 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|